Overview

* Ardelyx Q3 2025 product revenue grows 15% yr/yr to $105.5 mln

* IBSRELA Q3 revenue rises 92% yr/yr to $78.2 mln, guidance raised

* XPHOZAH Q3 revenue declines yr/yr due to Medicare coverage changes

Outlook

* Ardelyx ( ARDX ) raises 2025 IBSRELA revenue guidance to $270-275 mln

* Company expects continued growth for XPHOZAH in Q4 2025

Result Drivers

* IBSRELA GROWTH - IBSRELA revenue increased 92% yr/yr to $78.2 mln driven by strong demand and commercial execution

* XPHOZAH DECLINE - XPHOZAH revenue declined yr/yr due to Medicare coverage changes, but increased 9% from Q2 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $105.52

Product mln

Sales

Q3 Net -$969,00

Income 0

Q3 $101.68

Operatin mln

g

Expenses

Q3 $4.67

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Ardelyx Inc ( ARDX ) is $11.00, about 54.9% above its October 29 closing price of $4.96

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)